Our press releases
-
HOOKIPA Pharma Announces Pricing of Initial Public Offering
-
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
-
Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
-
Forbion analysis on European biotech landscape published in Nature Biotechnology
-
Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive Partnership for the Distribution of Curetis’ Unyvero
-
Enterprise Therapeutics strengthens leadership team, appoints Amit D. Munshi as Non-Executive Chairman
-
Inflazome receives funding from The Michael J. Fox Foundation for Parkinson’s Research
-
Data from SNF472 Phase 1b Clinical Trial published in British Journal of Clinical Pharmacology
-
uniQure to Participate in Multiple Upcoming Industry Conferences
-
uniQure Announces 2018 Financial Results and Highlights Recent Company Progress
-
uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
-
uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids
-
Gotham Therapeutics Strengthens Board of Directors and Scientific Advisory Board
-
OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter
-
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
-
Cellnovo announces its Q4 and Full Year 2018 Sales
-
Curetis’ Subsidiary Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test
-
Promedior Announces Pivotal Path for PRM-151 in Idiopathic Pulmonary Fibrosis Following Positive End-of-Phase 2 Meeting with FDA
-
Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia
-
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms
-
uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B
-
Forbion Appoints Dr. Carlo Incerti as Operating Partner
-
Forbion Leads €40m Series B Financing in Inflazome to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept
-
uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day
-
uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
-
Press Release: Icosabutate latest data shows direct and potent anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells
-
uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress
-
Forbion Leads €17m Series C Financing of OMEICOS Therapeutics
-
Milestone Pharmaceuticals Announces $80 Million Private Financing
-
JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
-
Data from first in-human clinical trial of SNF472 in haemodialysis patients published in British Journal of Clinical Pharmacology
-
New Data Presented at the European Society of Gene and Cell Therapy Annual Meeting Demonstrates up to 40 Times Higher Liver Expression with Optimized Promoter
-
uniQure Inc. - uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
-
Forbion Co-leads $54m Series A Financing in newly formed Gotham Therapeutics
-
Forbion closes oversubscribed fourth life sciences VC fund at EUR 360 million
-
uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
-
Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1
-
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti- PD-L1 Immunotherapy
-
KaNDy Therapeutics successfully raises £25 million in a Series C financing
-
uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
-
Escalier Doses First Patient with ESR-114 and Announces Clinical Advisory Board
-
Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes
-
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
-
Sanifit announces completion of enrollment in CaLIPSO – its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis
-
Forbion Portfolio Company Replimune Successfully Completes IPO on NASDAQ
-
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
-
Forbion exceeds target with EUR 270 million first close of its fourth life sciences VC fund
-
Hookipa Appoints Dr. Christoph Lengauer as a Non-Executive Director
-
uniQure Inc. - uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
-
Bio-Techne To Acquire Exosome Diagnostics, Inc.
